BRYN MAWR TRUST Co acquired a new stake in shares of Edwards Lifesciences Corp (NYSE:EW) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,646 shares of the medical research company’s stock, valued at approximately $298,000.

Several other institutional investors also recently added to or reduced their stakes in EW. Bank of New York Mellon Corp raised its position in shares of Edwards Lifesciences by 45.7% during the fourth quarter. Bank of New York Mellon Corp now owns 7,580,924 shares of the medical research company’s stock valued at $854,444,000 after buying an additional 2,377,444 shares during the last quarter. Atlantic Trust Group LLC raised its position in shares of Edwards Lifesciences by 734.7% during the third quarter. Atlantic Trust Group LLC now owns 914,989 shares of the medical research company’s stock valued at $100,018,000 after buying an additional 805,370 shares during the last quarter. Two Sigma Advisers LP raised its position in shares of Edwards Lifesciences by 827.6% during the fourth quarter. Two Sigma Advisers LP now owns 855,189 shares of the medical research company’s stock valued at $96,388,000 after buying an additional 763,000 shares during the last quarter. Alliancebernstein L.P. raised its position in shares of Edwards Lifesciences by 12.1% during the fourth quarter. Alliancebernstein L.P. now owns 6,259,771 shares of the medical research company’s stock valued at $705,539,000 after buying an additional 675,216 shares during the last quarter. Finally, Two Sigma Investments LP raised its position in shares of Edwards Lifesciences by 488.1% during the fourth quarter. Two Sigma Investments LP now owns 708,644 shares of the medical research company’s stock valued at $79,871,000 after buying an additional 588,148 shares during the last quarter. Hedge funds and other institutional investors own 82.89% of the company’s stock.

How to Become a New Pot Stock Millionaire

Several equities research analysts have recently issued reports on EW shares. Guggenheim reiterated a “buy” rating and set a $162.00 price objective on shares of Edwards Lifesciences in a research report on Friday, February 2nd. Stifel Nicolaus reiterated a “buy” rating and set a $155.00 price objective on shares of Edwards Lifesciences in a research report on Friday, February 2nd. Canaccord Genuity restated a “buy” rating and issued a $174.00 price target (up previously from $140.00) on shares of Edwards Lifesciences in a research report on Friday, February 2nd. Cowen restated a “buy” rating and issued a $150.00 price target on shares of Edwards Lifesciences in a research report on Thursday, February 1st. Finally, SunTrust Banks restated a “buy” rating and issued a $150.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, January 31st. Three research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $144.16.

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $114.97, for a total transaction of $3,771,016.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock in a transaction on Thursday, December 28th. The stock was sold at an average price of $114.08, for a total transaction of $604,624.00. The disclosure for this sale can be found here. Insiders have sold 142,903 shares of company stock valued at $17,850,415 over the last ninety days. 2.13% of the stock is owned by insiders.

Edwards Lifesciences Corp (NYSE EW) opened at $137.30 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.41 and a current ratio of 1.80. The company has a market cap of $29,684.75, a price-to-earnings ratio of 47.67, a price-to-earnings-growth ratio of 2.07 and a beta of 0.56. Edwards Lifesciences Corp has a one year low of $92.44 and a one year high of $143.22.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.91 by $0.03. The company had revenue of $888.50 million during the quarter, compared to analyst estimates of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.78%. Edwards Lifesciences’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.75 earnings per share. equities analysts anticipate that Edwards Lifesciences Corp will post 4.52 EPS for the current fiscal year.

Edwards Lifesciences declared that its board has approved a stock repurchase program on Thursday, December 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

ILLEGAL ACTIVITY WARNING: This piece was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/bryn-mawr-trust-co-acquires-shares-of-2646-edwards-lifesciences-corp-ew/1959110.html.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.